Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) announced the appointment of Virginia Alling as an independent director, subject to regulatory approval, further strengthening its board with Wall Street expertise to drive U.S. market expansion. Alling joins recent appointees Jeffrey J. Kraws and Christopher A. Van Buren, positioning the company for accelerated capital market access and strategic growth.
Alling brings over 30 years of experience in corporate banking, capital markets, and strategic advisory. She currently serves as Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, managing a multi-billion-dollar corporate client portfolio. Her expertise includes M&A, IPOs, ESOPs, leveraged finance, and revenue optimization. Previously, she held roles at JPMorgan Chase and Wells Fargo. A Registered Investment Adviser with FINRA Series 7 & 63 licenses, she holds an MBA from the College of William & Mary.
"We are thrilled to welcome Virginia Alling to our board," said Brent Willis, Voyageur’s CEO. "Her excellent track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements our recent appointments. We believe that Virginia’s deep experience in M&A and capital markets will be instrumental in unlocking institutional U.S. investment, streamlining our US market entry, and ensuring robust governance as we scale our innovative barium and iodine pipeline."
The strengthened board underscores Voyageur’s commitment to assembling high-calibre financial expertise to facilitate U.S. market expansion. Their collective experience in revenue generation, IPO execution, and regulatory compliance is expected to support commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations.
Voyageur is developing pharmaceutical-grade barium and iodine for medical imaging contrast media. The company owns a 100% interest in the Frances Creek barium sulphate project, which offers a rare high-grade mineral suitable for the pharmaceutical market. Voyageur aims to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw materials to final production. For more information, visit https://voyageurpharmaceuticals.ca.
